Skip to content

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie Renee Brahmer, Karen L. Reckamp, Lucio Crinò, Wilfried Eberhardt, Elena V Poddubskaya, Scott Joseph Antonia, Adam Płużański, Everett E. Vokes, Esther Holgado, David Michael Waterhouse, Neal Ready, Justin F. Gainor, Osvaldo Arén Frontera, Libor Havel, Martin B. Steins, Marina Chiara Garassino, Joachim G.J.V. Aerts, Manuel Dómine, Luis G Paz-Ares, Martin Reck, Christine Baudelet, Christopher T. Harbison, Brian Joseph Lestini, David Robert Spigel

New England Journal of Medicine · 2015 · 8,551 citationsOpen access

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Brahmer, J. R., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W., Poddubskaya, E. V., Antonia, S. J., Płużański, A., Vokes, E. E., Holgado, E., Waterhouse, D. M., Ready, N., Gainor, J. F., Frontera, O. A., Havel, L., Steins, M. B., Garassino, M. C., Aerts, J. G., Dómine, M., … Spigel, D. R. (2015). Nivolumab versus docetaxel in advanced squamous-cell Non–Small-Cell lung cancer. New England Journal of Medicine, 373(2), 123–135. https://doi.org/10.1056/nejmoa1504627

In text: (Brahmer et al., 2015)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

BACKGROUND: Patients with advanced squamous-cell non-small-cell lung cancer (NSCLC) who have disease progression during or after first-line chemotherapy have limited treatment options. This randomized, open-label, international, phase 3 study evaluated the efficacy and safety of nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, as compared with docetaxel in this patient population. METHODS: We randomly assigned 272 patients to receive nivolumab, at a dose of 3 mg per kilogram of body weight every 2 weeks, or docetaxel, at a dose of 75 mg per square meter of body-surface area every 3 weeks. The primary end point was overall survival. RESULTS: The median overall survival was 9.2 months (95% confidence interval [CI], 7.3 to 13.3) with nivolumab versus 6.0 months (95% CI, 5.1 to 7.3) with docetaxel. The risk of death was 41% lower with nivolumab than with docetaxel (hazard ratio, 0.59; 95% CI, 0.44 to 0.79; P<0.001). At 1 year, the overall survival rate was 42% (95% CI, 34 to 50) with nivolumab versus 24% (95% CI, 17 to 31) with docetaxel. The response rate was 20% with nivolumab versus 9% with docetaxel (P=0.008). The median progression-free survival was 3.5 months with nivolumab versus 2.8 months with docetaxel (hazard ratio for death or disease progression, 0.62; 95% CI, 0.47 to 0.81; P<0.001). The expression of the PD-1 ligand (PD-L1) was neither prognostic nor predictive of benefit. Treatment-related adverse events of grade 3 or 4 were reported in 7% of the patients in the nivolumab group as compared with 55% of those in the docetaxel group. CONCLUSIONS: Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level. (Funded by Bristol-Myers Squibb; CheckMate 017 ClinicalTrials.gov number, NCT01642004.).

  1. PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer2016
  2. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma2010
  3. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review2017
  4. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer2012
  5. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer2016

Metadata from OpenAlex (CC0). Citations are generated from the published record.